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The Increase in Neonatal Abstinence Syndrome from Opioids
Affects Us All
Sean Withington and Shannon M. Monnat
Opioid misuse and dependence during
pregnancy has increased dramatically in the
U.S. in recent years, paralleling the increase in
opioid use disorders seen in the general U.S.
population. This has resulted in a rapid increase
in the number of babies who are born with
neonatal abstinence syndrome (NAS) physical dependence on opioids. Cases of NAS
nearly doubled from 13,500 in 2009 to
25,000 in 2016 and continue to rise.1
Resulting from exposure to opioids in the
womb, newborn babies begin to develop the
symptoms of physical withdrawal within 48
hours of birth. Symptoms include extreme
sensitivity to touch and light, a high-pitched
cry, an abnormally high heart rate, overactive
reflexes, seizures, and tremors. At least 50
percent of babies exposed to opioids during
pregnancy will develop opioid dependency,
increasing the risk of birth complications, low
birth weight, respiratory problems,
underdevelopment in the womb, and even
death.2

The Costs of NAS are Substantial
Compared to an average 5-day hospital stay for
newborns without NAS, opioid-exposed babies
require an average 17-day hospital stay after
birth. The hospital cost is more than three times
higher for an infant born with NAS (average
cost of $16,893) compared to an infant
without NAS (average cost of $5,610).3
Additional outpatient treatment after discharge
increases the costs of NAS even more, to up to
$238,000 above that of an unaffected
newborn.4 Because opioid dependence is more

prevalent among low-income populations, a
substantial portion of the treatment costs for
NAS fall on state Medicaid budgets. From
2004 to 2014, NAS resulted in approximately
$2 billion in excess Medicaid costs.5 Some state
budgets have been hit especially hard. For
example, NAS cost Missouri’s Medicaid budget
$10 million in 2016. Rates of NAS in
Pennsylvania increased by over 1,000 percent
between 2000 and 2018, 5 with a cost of $14.1
million to its Medicaid budget in 2017 alone.
This added burden to state Medicaid budgets
means that other essential services could go
underfunded.
The costs go beyond the financial. NAS
heightens the probability of developing an
educational disability and speech or language
impairments in early childhood and increases
the likelihood of requiring classroom support or
speech therapy by a third.6 Not only does this
increase the burden on stretched public
resources, but it also reduces the probability
that these children will reach their full
productive potential. Ultimately, NAS and the
opioid crisis more broadly have major human
and societal costs.

We Must Address the Root Causes
of Addiction
Many people see NAS as purely the result of a
voluntary drug habit of an irresponsible mother.
This view ignores the physiological and social
realities of addiction. Addiction is a chronic
relapsing brain disease, with roots in individual
early-life trauma and broader economic and
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social despair.7 Adverse childhood experiences,
like abuse, witnessing parental domestic
violence, and parental incarceration or death
place children at higher risk of developing
substance abuse and mental health disorders in
adulthood.8 In addition, we cannot fully
understand or reverse the opioid crisis without
considering its social determinants. Social
determinants of health are the structural
conditions in which people live, work, and
socialize that influence stress, health behaviors,
and mortality, including economic resources,
social relationships, and labor markets. At a
societal level, thanks to several decades of
economic and social decline in once thriving
communities, many places in the U.S. were
primed to be vulnerable to opioids – drugs that
numb both physical and psychological pain.9
Addressing NAS requires addressing opioid
addiction, but more broadly requires reversing
social and economic distress and despair.

Further Action is Necessary
There are no easy solutions to the opioid crisis.
In the short term, strategies to reduce NAS
should focus on encouraging stigma-free
treatment for women with addictions who
become pregnant. We must also understand
that mothers continue to need support after
delivery. By making treatment more accessible,
women may be more inclined to seek help. This
is gradually beginning to take place. In 2016,
the Child Abuse Prevention and Treatment Act
(CAPTA) was amended in conjunction with
the Comprehensive Addiction and Recovery
Act (CARA) to begin awarding funds to states
in support of NAS treatment. In 2018, New
York State allocated $3.6 million of CAPTA
funding to the treatment of NAS and support
for mothers with opioid addiction or
dependence. As stipulated by CARA, this
funding has led to the development of a
program that will provide a plan of safe care for
all babies identified as suffering from NAS and
prioritizes keeping mothers with their babies
during treatment. New York’s approach may

become an example of the way forward, but
there is much more to do.
At the national level, NAS has drawn far less
attention from policymakers than it should. A
centralized strategy to reduce, rather than just
treat, NAS is only starting to take shape as part
of the SUPPORT for Patients and
Communities Act of 2018, but this may not be
formalized for another year. With so much at
stake, it is important that policymakers at all
levels take a more proactive approach to
reverse the trend of increasing NAS rates.
Additionally, a wholesale re-evaluation of our
stigma toward pregnant women who use drugs
will be necessary for any lasting impact. In 18
states, child abuse proceedings are still explicitly
permitted to charge pregnant women for drug
use during pregnancy.11 Tennessee went as far
as to introduce legislation to criminalize the use
of opioids during pregnancy, but allowed it to
expire in 2016 after it failed to prevent a
continued rise in rates. It is time to critically
reassess the idea that criminalization will reduce
rates of addiction and NAS and begin treating
addiction as the population health issue that it
is. Given the human and financial costs, failure
to effectively tackle opioid addiction and
prevent NAS affects us all, regardless of
whether we personally know someone who is
dealing with addiction.
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